Elagolix, an oral GnRH antagonist for endometriosisassociated pain

A randomized controlled study

Bruce Carr, Linda Giudice, W. Paul Dmowski, Chris O'Brien, Ping Jiang, Joshua Burke, Roland Jimenez, Steven Hass, Mahesh Fuldeore, Kristof Chwalisz

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. Methods: This was a phase II, randomized, placebo-controlled parallel group study conducted at 37 US centers, consisting of an 8-week double-blind period followed by a 16-week open-label period. Patients were 137 women aged 18 to 49, with laparoscopically confirmed endometriosis and moderate to severe nonmenstrual pelvic pain and dysmenorrhea, who were administered elagolix 150 mg daily or placebo. The primary outcomes of the study were the daily assessment of dysmenorrhea, nonmenstrual pelvic pain and dyspareunia using a modified Biberoglu-Behrman scale. Results: During the double-blind period, there were significantly greater mean reductions from baseline to week 8 in dysmenorrhea (-1.13 ± 0.11 vs. -0.37 ± 0.11, p<0.0001), nonmenstrual pelvic pain (-0.47 ± 0.07 vs. -0.19 ± 0.07, p = 0.0066), and dyspareunia scores (-0.61 ± 0.10 vs. -0.23 ± 0.10, p = 0.0070) in the elagolix group compared with placebo. Continued improvements were observed during the open-label treatment regardless of initial treatment allocation. Elagolix treatment was also associated with significant improvements in quality-of-life measures during the double-blind and open-label periods. The most common adverse events occurring with elagolix were nausea, headache and hot flush, each in 9.9% of patients. Conclusion: Elagolix effectively reduced endometriosis-associated pelvic pain over a 24-week period and was well-tolerated.

Original languageEnglish (US)
Pages (from-to)105-115
Number of pages11
JournalJournal of Endometriosis
Volume5
Issue number3
DOIs
StatePublished - Jul 2013

Fingerprint

Hormone Antagonists
Pelvic Pain
Gonadotropin-Releasing Hormone
Pain
Dysmenorrhea
Endometriosis
Dyspareunia
Placebos
Therapeutics
Nausea
Headache
elagolix
Quality of Life
Outcome Assessment (Health Care)

Keywords

  • Elagolix
  • Endometriosis
  • GnRH antagonists
  • Pelvic pain

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Carr, B., Giudice, L., Dmowski, W. P., O'Brien, C., Jiang, P., Burke, J., ... Chwalisz, K. (2013). Elagolix, an oral GnRH antagonist for endometriosisassociated pain: A randomized controlled study. Journal of Endometriosis, 5(3), 105-115. https://doi.org/10.5301/je.5000157

Elagolix, an oral GnRH antagonist for endometriosisassociated pain : A randomized controlled study. / Carr, Bruce; Giudice, Linda; Dmowski, W. Paul; O'Brien, Chris; Jiang, Ping; Burke, Joshua; Jimenez, Roland; Hass, Steven; Fuldeore, Mahesh; Chwalisz, Kristof.

In: Journal of Endometriosis, Vol. 5, No. 3, 07.2013, p. 105-115.

Research output: Contribution to journalArticle

Carr, B, Giudice, L, Dmowski, WP, O'Brien, C, Jiang, P, Burke, J, Jimenez, R, Hass, S, Fuldeore, M & Chwalisz, K 2013, 'Elagolix, an oral GnRH antagonist for endometriosisassociated pain: A randomized controlled study', Journal of Endometriosis, vol. 5, no. 3, pp. 105-115. https://doi.org/10.5301/je.5000157
Carr, Bruce ; Giudice, Linda ; Dmowski, W. Paul ; O'Brien, Chris ; Jiang, Ping ; Burke, Joshua ; Jimenez, Roland ; Hass, Steven ; Fuldeore, Mahesh ; Chwalisz, Kristof. / Elagolix, an oral GnRH antagonist for endometriosisassociated pain : A randomized controlled study. In: Journal of Endometriosis. 2013 ; Vol. 5, No. 3. pp. 105-115.
@article{1b4bc8ad1fde4d51a64c8086613ebe6c,
title = "Elagolix, an oral GnRH antagonist for endometriosisassociated pain: A randomized controlled study",
abstract = "Objective: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. Methods: This was a phase II, randomized, placebo-controlled parallel group study conducted at 37 US centers, consisting of an 8-week double-blind period followed by a 16-week open-label period. Patients were 137 women aged 18 to 49, with laparoscopically confirmed endometriosis and moderate to severe nonmenstrual pelvic pain and dysmenorrhea, who were administered elagolix 150 mg daily or placebo. The primary outcomes of the study were the daily assessment of dysmenorrhea, nonmenstrual pelvic pain and dyspareunia using a modified Biberoglu-Behrman scale. Results: During the double-blind period, there were significantly greater mean reductions from baseline to week 8 in dysmenorrhea (-1.13 ± 0.11 vs. -0.37 ± 0.11, p<0.0001), nonmenstrual pelvic pain (-0.47 ± 0.07 vs. -0.19 ± 0.07, p = 0.0066), and dyspareunia scores (-0.61 ± 0.10 vs. -0.23 ± 0.10, p = 0.0070) in the elagolix group compared with placebo. Continued improvements were observed during the open-label treatment regardless of initial treatment allocation. Elagolix treatment was also associated with significant improvements in quality-of-life measures during the double-blind and open-label periods. The most common adverse events occurring with elagolix were nausea, headache and hot flush, each in 9.9{\%} of patients. Conclusion: Elagolix effectively reduced endometriosis-associated pelvic pain over a 24-week period and was well-tolerated.",
keywords = "Elagolix, Endometriosis, GnRH antagonists, Pelvic pain",
author = "Bruce Carr and Linda Giudice and Dmowski, {W. Paul} and Chris O'Brien and Ping Jiang and Joshua Burke and Roland Jimenez and Steven Hass and Mahesh Fuldeore and Kristof Chwalisz",
year = "2013",
month = "7",
doi = "10.5301/je.5000157",
language = "English (US)",
volume = "5",
pages = "105--115",
journal = "Journal of Endometriosis",
issn = "2035-9969",
publisher = "Wichtig Publishing",
number = "3",

}

TY - JOUR

T1 - Elagolix, an oral GnRH antagonist for endometriosisassociated pain

T2 - A randomized controlled study

AU - Carr, Bruce

AU - Giudice, Linda

AU - Dmowski, W. Paul

AU - O'Brien, Chris

AU - Jiang, Ping

AU - Burke, Joshua

AU - Jimenez, Roland

AU - Hass, Steven

AU - Fuldeore, Mahesh

AU - Chwalisz, Kristof

PY - 2013/7

Y1 - 2013/7

N2 - Objective: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. Methods: This was a phase II, randomized, placebo-controlled parallel group study conducted at 37 US centers, consisting of an 8-week double-blind period followed by a 16-week open-label period. Patients were 137 women aged 18 to 49, with laparoscopically confirmed endometriosis and moderate to severe nonmenstrual pelvic pain and dysmenorrhea, who were administered elagolix 150 mg daily or placebo. The primary outcomes of the study were the daily assessment of dysmenorrhea, nonmenstrual pelvic pain and dyspareunia using a modified Biberoglu-Behrman scale. Results: During the double-blind period, there were significantly greater mean reductions from baseline to week 8 in dysmenorrhea (-1.13 ± 0.11 vs. -0.37 ± 0.11, p<0.0001), nonmenstrual pelvic pain (-0.47 ± 0.07 vs. -0.19 ± 0.07, p = 0.0066), and dyspareunia scores (-0.61 ± 0.10 vs. -0.23 ± 0.10, p = 0.0070) in the elagolix group compared with placebo. Continued improvements were observed during the open-label treatment regardless of initial treatment allocation. Elagolix treatment was also associated with significant improvements in quality-of-life measures during the double-blind and open-label periods. The most common adverse events occurring with elagolix were nausea, headache and hot flush, each in 9.9% of patients. Conclusion: Elagolix effectively reduced endometriosis-associated pelvic pain over a 24-week period and was well-tolerated.

AB - Objective: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. Methods: This was a phase II, randomized, placebo-controlled parallel group study conducted at 37 US centers, consisting of an 8-week double-blind period followed by a 16-week open-label period. Patients were 137 women aged 18 to 49, with laparoscopically confirmed endometriosis and moderate to severe nonmenstrual pelvic pain and dysmenorrhea, who were administered elagolix 150 mg daily or placebo. The primary outcomes of the study were the daily assessment of dysmenorrhea, nonmenstrual pelvic pain and dyspareunia using a modified Biberoglu-Behrman scale. Results: During the double-blind period, there were significantly greater mean reductions from baseline to week 8 in dysmenorrhea (-1.13 ± 0.11 vs. -0.37 ± 0.11, p<0.0001), nonmenstrual pelvic pain (-0.47 ± 0.07 vs. -0.19 ± 0.07, p = 0.0066), and dyspareunia scores (-0.61 ± 0.10 vs. -0.23 ± 0.10, p = 0.0070) in the elagolix group compared with placebo. Continued improvements were observed during the open-label treatment regardless of initial treatment allocation. Elagolix treatment was also associated with significant improvements in quality-of-life measures during the double-blind and open-label periods. The most common adverse events occurring with elagolix were nausea, headache and hot flush, each in 9.9% of patients. Conclusion: Elagolix effectively reduced endometriosis-associated pelvic pain over a 24-week period and was well-tolerated.

KW - Elagolix

KW - Endometriosis

KW - GnRH antagonists

KW - Pelvic pain

UR - http://www.scopus.com/inward/record.url?scp=84884915358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884915358&partnerID=8YFLogxK

U2 - 10.5301/je.5000157

DO - 10.5301/je.5000157

M3 - Article

VL - 5

SP - 105

EP - 115

JO - Journal of Endometriosis

JF - Journal of Endometriosis

SN - 2035-9969

IS - 3

ER -